1. Southorn PA. Free radicals in medicine: 1. chemical nature and biologic reactions. Mayo Clin Proc 1988;63:381.
2. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. New York: Oxford University Press, 1985:139.
3. Hogg N, Kalyanaraman B, Joseph J, et al. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett 1993;334:170.
4. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human diseases: an overview. Methods Enzymol 1990;186:1.
5. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982;47:412.
6. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70:593.
7. Feng L, Andalibi A, Qiao JH, et al. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994;94:877.
8. Kuhn H, Belkner J, Suzuki H, et al. Oxidative modification of human lipoproteins by lipoxygenases of different positional specificities. J Lipid Res 1994;35:1749.
9. Yla-Hertuala S, Rosenfeld ME, Parthasarathy S, et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 1990;87:6959.
10. Kim J, Gu J, Natarajan R, et al. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Arterioscler Thromb Vasc Biol 1995;15:942.
11. Natarajan R, Gu JL, Rossi J, et al. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA 1993;90:4947.
12. Natarajan R, Bai W, Rangarajan V, et al. Platelet-derived growth factor BB mediated regulation of 12-lipoxygenase in porcine VSMC. J Cell Physiol 1996;169:391.
13. Natarajan R, Rosdahl J, Gonzales N, et al. Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells. Hypertension 1997;30:873.
14. Natarajan R, Gonzales N, Lanting L, et al. Role of the lipoxygenase pathway in angiotensin II–induced vascular smooth muscle cell hypertrophy. Hypertension 1994;23:I-142.
15. Nadler JL, Natarajan R, Stern N. Specific action of the lipoxygenase pathway in mediating angiotensin II–induced aldosterone synthesis in isolated adrenal glomerulosa cells. J Clin Invest 1987;80:1763.
16. Gu J, Natarajan R, Ben-Ezra J, et al. Evidence that a leukocyte type of 12-lipoxygenase is expressed and regulated by angiotensin II in human adrenal glomerulosa cells. Endocrinology 1994;134:70.
17. Nozawa K, Tuck M, Golub M, et al. Inhibition of the lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am J Physiol 1990;259:H174.
18. Nakao J, Ooyama T, Ito H, et al. Comparative effect of lipoxygenase products of arachidonic acid on rat aortic smooth muscle cell migration. Atherosclerosis 1982;44:339.
19. Antonipillai I, Nadler JL, Robin EC, et al. The inhibitory role of 12- and 15-lipoxygenase products on renin release. Hypertension 1987;10:61.
20. Natarajan R, Lanting L, Xu L, et al. Role of specific isoforms of protein kinase C in angiotensin II and lipoxygenase action in rat adrenal glomerulosa cells. Mol Cell Endocrinol 1994;101:59.
21. Haliday E, Ramesha C, Ringold G. TNF induces c-fos via a novel pathway requiring conversion of arachidonic acid to a lipoxygenase metabolite. EMBO J 1991;10:109.
22. Rao G, Bass AS, Glasgow WC, et al. Activation of MAP kinases by arachidonic acid and its metabolites in vascular smooth muscle cells. J Biol Chem 1994;269:32586.
23. Wen Y, Nadler JL, Gonzales N, et al. Mechanisms of ANG II–induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase. Am J Physiol 1996;271:C1212.
24. Wen Y, Scott S, Liu Y, et al. Evidence that angiotensin II and lipoxygenase products activate c-jun NH2-terminal kinase. Circ Res 1997; 81:651.
25. Roy P, Roy SK, Mitra A, et al. Superoxide generation by lipoxygenase in the presence of NADH and NADPH. Biochim Biophys Acta 1994; 1214:171.
26. Laniado-Schwartzman M, Lavrovsky Y, Stoltz R, et al. Activation of nuclear factor kB and oncogene expression by 12(R)-hydroxyeicosatrienoic acid, and angiogenic factor in microvessel endothelial cells. J Biol Chem 1994;269:24321.
27. Natarajan R, Wei B, Lanting L, et al. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 1997;273:H2224.
28. Zhao L, Cuff CA, Moss E, et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase–deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 2002;277(38):35350–35356.
29. Natarajan R, Nadler JL. Lipoxygenase and lipid signaling in vascular cells in diabetes cellular and molecular mechanisms of diabetes-accelerated atherosclerosis: frontiers in bioscience. In: Bornfeldt KE, ed. Webjournal: Frontiers in Bioscience, http://www.Bioscience.org.
30. Morrow JD, Awad JA, Hollis JB, et al. Non–cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992;89:10721.
31. Patrono C. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17: 2309.
32. Fukunaga M, Makita N, Roberts JL, et al. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 1993;264:1619.
33. Natarajan R, Lanting L, Nadler J. Formation of a F2-isoprostane, 8-epi-prostaglandin F2a in vascular smooth muscle cells (VSMC) by elevated glucose and growth factors. Am J Physiol 1996;271:H159.
34. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999;99:224.
35. Frank L, Massaro D. Oxygen toxicity. Am J Med 1980;69:117.
36. Murad F. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Rec Prog Horm Res 1998;53:43.
37. Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int Suppl 1996;55:S2.
38. Xie O, Nathan C. The high output nitric oxide pathway: role and regulation. J Leukoc Biol 1994;56:576.
39. Stamler JS. Redox signalling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931.
40. Schmidt HH, Lohmann S, Walter U. The nitric oxide and cGMP signal transduction system. Biochim Biophys Acta 1993;1178:153.
41. Hirata K, Miki N, Kuroda Y, et al. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995;76:958–962.
42. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, P13-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539–1545.
43. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101:676–681.
44. Steinberg H, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172.
45. Weiner C, Lizasoain I, Baylis S, et al. Induction of calcium-dependent nitric oxide by sex hormones. Proc Natl Acad Sci USA 1994;91: 5212.
46. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000;342:454–460.
47. Yoshizumi M, Perrella MA, Burnett JC Jr, et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73:205–209.
48. Balon TW, Nadler JL. Nitric oxide release is present in skeletal muscle. J Appl Physiol 1994;77:2519.
49. Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res 1993;73:217.
50. Williams IL, Wheatcroft SB, Shah AM, et al. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obesity 2002;26:754–764.
51. Ito S, Johnson CS, Carretero OA. Modulation of angiotensin II–induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1991;87:1656.
52. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002.
53. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651.
54. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774.
55. Kourembanas S, McQuillan LP, Leung GK, et al. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993;92:99.
56. Cooke JP, Singer AH, Tsao P, et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168.
57. Rengasamy A, Johns RA. Inhibition of nitric oxide synthase by a superoxide generating system. J Pharmacol Exp Ther 1993;267:1024.
58. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87:1620.
59. White CR, Brock TA, Chang L-Y, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044.
60. Chang GJ, Woo P, Honda HM, et al. Oxidation of LDL to a biologically active form by derivatives of nitric oxide and nitrite in the absence of superoxide. Arterioscler Thromb 1994;14:1808.
61. Rösen P, Du X, Sui GZ. Molecular mechanisms of endothelial dysfunction in the diabetic heart. In: Angel A, Dhalla NS, Pierce GN et al., eds. Diabetes and cardiovascular disease: etiology, treatment and outcomes. New York: Kluwer Academic/Plenum Publishers 2001:75–86.
62. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599–622.
63. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820.
64. Ido Y, Kilo C, Williamson JR. Cytosolic NADH/NAD+, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia 1997;40(suppl):115.
65. Jiang Z-Y, Woolard ACS, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett 1990;268:69.
66. Thornalley P, Wolff S, Crabbe M, et al. The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. Biochim Biophys Acta 1984;797:276.
67. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation: glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and aging. Biochem J 1988;256:205.
68. Yerneni KKV, Bai W, Khan BV, et al. Hyperglycemia-induced activation of nuclear transcription factor κB in vascular smooth muscle cells. Diabetes 1999;48:855.
69. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996;25: 255–270.
70. Hicks M, Delbridge L, Yue DK, et al. Catalysis of lipid peroxidation by glucose and glycosylated collagen. Biochem Biophys Res Commun 1988;151:649.
71. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994; 94:771.
72. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells. Circulation 2003;107:1017–1023.
73. Natarajan R, Gonzales N, Xu L, et al. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 1992;187:552.
74. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859.
75. Natarajan R, Scott S, Bai W, et al. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension 1999;33:378.
76. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999;103:185.
77. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998;31:152.
78. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB dependent fashion. J Clin Invest 1998;101: 1905–1915.
79. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000;58(suppl 77):113–119.
80. Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Horm Res 2000;53:53–67.
81. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115–126. [Review of the inflammatory mechanisms that contribute to the development and progression of atherosclerosis.]
82. Craven PA, Melham MF, Phillip SL. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001;50:2114–2125.
83. Kim JA, Berliner JA, Natarajan R, et al. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 1994;43:1103.
84. Rattan V, Yamin S, Sultana C, et al. Glucose-induced transmigration of monocytes is linked to phosphorylation of PECAM-1 in culture endothelial cells. Am J Physiol 1996;271:E711.
85. Kim PM, Kim JA, Harper CM, et al. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arteriosclerosis Thromb Vasc Biol 1999;19:2615–2622.
86. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000;17:171–180.
87. Nakao-Hayashi J, Ito H, Kawashima S. An oxidative mechanism is involved in high glucose-induced serum protein modification causing inhibition of endothelial cell proliferation. Atherosclerosis 1992;97:89.
88. Curcio F, Ceriello A. Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell Dev Biol 1992;28A:787.
89. Kashiwagi A, Asahina T, Nishio Y, et al. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 1996;45(suppl):84.
90. Sharpe PC, Yue KKM, Catherwood MA, et al. The effects of glucose-induced oxidative stress on growth and extracellular matrix gene expression of vascular smooth muscle cells. Diabetologia 1998;41:1210.
91. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diebetologia 2003;46(suppl 1):M9–M16.
92. Diwadkar VA, Anderson JW, Bridges SR, et al. Postprandial low density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999;222:178–184.
93. Ahmed MU, Thorpe SR, Baynes JW. Identification of N-carboxymethyl-lysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889.
94. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315.
95. Mullarley CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990;173:932.
96. Sakurai T, Sugioka K, Nakano M. O2-generation and lipid peroxidation during the oxidation of a glycated polypeptide, glycated polylysine, in the presence of iron-ADP. Biochim Biophys Acta 1990; 1043:27.
97. Hunt JV, Smith CCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990;39:1420.
98. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405.
99. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481–1490.
100. Arai K, Maguchi S, Fujii S, et al. Glycation and inactivation of human Cu-Zn-superoxide dismutase: identification of the in vitro glycated sites. J Biol Chem 1987;262:16969.
101. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications. Diabetes 1999;48:1.
102. Wolff SP, Dean RT. Glucose autoxidation and protein modification: the potential role of autoxidative glycosylation in diabetes. Biochem J 1987;245:243.
103. Ceriello A, Giugliano D, Quatraro A, et al. Vitamin E reduction of protein glycosylation in diabetes: new prospect for prevention of diabetic complications? Diabetes Care 1991;14:68.
104. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997;100:2995.
105. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 1994;94:110–117.
106. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432–438.
107. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int 2000;58 (suppl):26–30.
108. Culotta VC. Superoxide dismutase, oxidative stress, and cell metabolism. Curr Top Cell Regul 2000;36:117–132.
109. Opara EC, Abdel-Rahman E, Soliman S, et al. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism 1999;48:1414–1417.
110. Maxwell SRJ, Thomason H, Sandler D, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non–insulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27:484–490.
111. Uchimura K, Nagasaka A, Hayashi R, et al. Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. J Diabetes Complications 1999;13:264–270.
112. Ceriello A, Giugliano D, Quatraro A, et al. Metabolic control may influence the increased superoxide generation in diabetic serum. Diabet Med 1991;8:541.
113. Tsai EC, Hirsch IB, Brunzell JD, et al. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994;43:1010.
114. Altomare E, Vendemiale G, Chicco D, et al. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabetes Metab 1992;18:264.
115. Santini SA, Marra G, Giardina B, et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 1997;46:1853–1858.
116. Jain SK, McVie R, Duett J, et al. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 1989;38: 1539.
117. Rajeswari P, Natarajan R, Nadler JL, et al. Glucose induces lipid peroxidation and inactivation of membrane-associated ion-transport enzymes in human erythrocytes in vivo and in vitro. J Cell Physiol 1991;149:100.
118. Antonipillai I, Nadler J, Jost-Vu E, et al. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 1996;81:1940.
119. Gerrity RG, Nadler JL, Natarajan R. Oxidant stress in a new swine model of diabetes-induced accelerated atherosclerosis [Abstract]. Circulation 1997;96:I-175.
120. Gerrity RG, Natarajan R, Nadler JL, et al. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001;50:1654–1665.
121. Hofmann MA, Schiekofer S, Kanitz M, et al. Insufficient glycemic control increases nuclear factor-MB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998;21:1310.
122. Hofmann MA, Schiekofer S, Isermann B, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 1999;42:222–232.
123. Jain SK, McVie R, Jackson R, et al. Effect of hyperketonemia on plasma lipid peroxidation levels in diabetic patients. Diabetes Care 1999;22:1171–1175.
124. Valabhji J, McColl AJ, Richmond W, et al. Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care 2001;24:1608–1613.
125. Vucic M, Gavella M, Bozikov V, et al. Superoxide dismutase activity in lymphocytes and polymorphonuclear cells of diabetic patients. Eur J Clin Chem Clin Biochem 1997;35:517–521.
126. Yoshida K, Hirokawa J, Tagami S, et al. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995;38:201–210.
127. Obrosova IG, Fathallah L, Liu E, et al. Early oxidative stress in the diabetic kidney: effect of DL-α-lipoic acid. Free Radic Biol Med 2003;34:186–195.
128. Kakkar R, Mantha SV, Radhi J, et al. Antioxidant defense system in diabetic kidney: a time course study. Life Sci 1997;60:667–679.
129. Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46(suppl):38–42.
130. Li W, Yanoff M, Jian B, et al. Altered mRNA levels of antioxidant enzymes in pre-apoptotic pericytes from human diabetic retinas. Cell Mol Biol 1999;45:59–66.
131. Altomare E, Grattagliano I, Vendemaile G, et al. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur J Clin Invest 1997;99:457–468.
132. Gurler B, Vural H, Yilmar N, et al. The role of oxidative stress in diabetic retinopathy. Eye 2000;14:730–735.
133. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994;16:383.
134. Pieper GM, Mei DA, Langenstroer P, et al. Bioassay of endothelium-derived relaxing factor in diabetic rat aorta. Am J Physiol 1992;263: H676.
135. Tesfamariam B, Brown JL, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991;86:1643.
136. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats: evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 1994;93:311.
137. Hink U, Huige L, Hanke M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:e14–e22.
138. Gupta S, Sussman I, McArthur CS, et al. Endothelium-dependent inhibition of Na+-K+ ATPase activity in rabbit aorta by hyperglycemia: possible role of endothelium-derived nitric oxide. J Clin Invest 1992;90:727.
139. Gupta S, Tieken K, Ruderman N. Inhibition of nitric oxide synthase activity by hyperglycemia in endothelial cells [Abstract]. Diabetes 1994;43(suppl 1):100A.
140. Graier WF, Wascher TC, Lackner L, et al. Exposure to elevated d-glucose concentrations modulates vascular endothelial cell vasodilatatory response. Diabetes 1993;42:1497.
141. Langenstroer P, Pieper GM. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 1992; 263:H257.
142. Koo JR, Vaziri ND. Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int 2003;63:195–201.
143. Coffer MJ, Coles B, O’Donnell VB. Interactions of nitric oxide-derived reactive nitrogen species with peroxidases and lipoxygenase; Free Radic Res 2002;35:447–464.
144. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510.
145. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548.
146. Hogan M, Cerami A, Bucala R. Advanced glycosylation end products block the antiproliferative effect of nitric oxide: role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992;90:1110.
147. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42:221.
148. Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest 1994; 94:2511.
149. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444.
150. Steinberg D. Antioxidant vitamins and coronary heart disease. N Engl J Med 1993;328:1487.
151. Jain SK. Should high-dose vitamin E supplementation be recommended to diabetic patients? Diabetes Care 1999;22:1242–1243.
152. Bursell SE, Clermont AC, Aiello LP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999;22:1245–1251.
153. Kunisaki M, Bursell S-E, Umeda F, et al. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994;43:1372.
154. Gazis A, White DJ, Page SR, et al. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in type 2 diabetes mellitus. Diabet Med 1999;16:304–311.
155. The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. Effects of ramipril on cardiovascular and microvascular complications outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Study. Lancet 2000;355:253–259. [Demonstrated that ramipril treatment in patients with diabetes is associated with a reduction in cardiovascular events and mortality. This finding was only partially related to blood pressure reduction suggesting a direct vascular protective effect of ramipril.]
156. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein: when and how this antioxidant became a pro-oxidant. Biochem J 1992;288:341.
157. Hunt JV, Bottoms MA, Mitchinson MJ. Ascorbic acid oxidation: a potential cause of the elevated severity of atherosclerosis in diabetes mellitus? FEBS Lett 1992;311:161.
158. Young IS, Tate S, Lightbody JH, et al. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. Free Rad Biol Med 1995;18:833–840.
159. Mooradian AD. The effect of ascorbate and dehydroascorbate on tissue uptake of glucose. Diabetes 1987;36:1001.
160. Mayer-Davis EJ, Bell RA, Reboussin BA, et al. Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology 1998;105:2264–2270.
161. Mooradian AD, Failla M, Hoogwerf B, et al. Selected vitamins and minerals in diabetes. Diabetes Care 1994;17:464.
162. Zhang WJ, Frei B. α-Lipoic acid inhibits TNF-α-induced NF-κB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001;13:1845–1854.
163. Borcea V, Nourooz-Zadeh J, Wolf SP, et al. Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Rad Biol Med 1999;26:1495–1500.
164. Ziegler D, Feljanovic M, Mehnert H, et al. α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107:421–430.
165. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: a 4-month randomized controlled multicenter trial (DEKAN study). Diabetes Care 1997;20:369–373.
166. Morcos M, Borcea V, Isermann B, et al. Effect of α-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175–183.
167. Watts GF, Playford DA, Croft KD, et al. Coenzyme Q10 improves endothelial function of the brachial artery in type II diabetes mellitus. Diabetologia 2002;45:420–426.
168. McCarty MF. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med Hypotheses 1999;53:300–304.
169. Salvemini D, Wang ZQ, Zweier JL et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 1999;286:304–306.
170. Staprans I, Rapp JH, Pan X-M, et al. The effect of oxidized lipids in the diet on serum lipoprotein peroxides in control and diabetic rats. J Clin Invest 1993;92:638.
171. Nadler JL, Malayan S, Luong E, et al. Intracellular free magnesium plays a key role in increased platelet reactivity in type II diabetes. Diabetes Care 1992;15:835.
172. Resnick LM, Gupta RK, Bhargava KK, et al. Cellular ions in hypertension, diabetes and obesity. Hypertension 1991;17:951.
173. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 1992; 263:734.
174. Nadler JL, Buchanan T, Natarajan R, et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993;21:1024.
175. Schmidt LE, Arfken CL, Heins JM. Evaluation of nutrient intake in subjects with non-insulin-dependent diabetes mellitus. J Am Diet Assoc 1994;94:773.
176. Shechter M, Sharir M, Paul-Labrador M, et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102:2353–2358.
177. Shechter M, Bairey Merz CN, Stuehlinger HG, et al. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol 2003;91:517–521.
178. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148–1150.
179. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of α-tocopherol supplementation. Circulation 2000;102 (2):191–196.
180. Srinivasan S, Yeh M, Danziger EC, et al. Glucose regulates monocyte adhesion through endothelial production of interleukin-8. Circ Res 2003;92:371–377.
181. Renier G, Mamputu JC, Desfaits AC, et al. Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging. J Diabetes Complications 2003;17:20–29.
182. Yui S, Sasaki T, Araki N, et al. Induction of macrophage growth by advanced glycation end products of the Maillard reaction. J Immunol 1994;152:1943–1949.
183. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 2001;173:35–43.
184. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96(12): 4219–4225.
185. Stehouwer C, Gall MA, Twisk JWR, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated and independently associated with risk of death. Diabetes 2002;51:1157–1165.
186. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of α-tocopherol supplementation. Circulation 2000;102: 191–196.
187. Bagg W, Ferri C, Desideri G, et al. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:5491–5497.
188. Rasmussen LM, Schmitz O, Ledet T. Increased expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured endothelial cells exposed to serum from type 1 diabetic patients: no effects of high glucose concentrations. Scand J Clin Lab Invest 2002;62:485–494.
189. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
190. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–369.
191. Festa A, D’Agostino RJ, Howard G, et al. Chronic subclinical inflammation as part of insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
192. Pasceri V, Wilkerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165–2168.
193. Ridker PM. High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813–1818.
194. Danesh J, Whincup P, Walker M, et al. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199–204.
195. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338–3342.
196. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
197. Ridker PM. Physician’s Health Study. Ann Intern Med 1999;130: 933–937.
198. Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolism syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25:2016–2021.
199. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391–397.
200. Chinetti G, Fruchart JC, Staels B. Peroxisome-proliferator–activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Res 2000;49:497–505.
201. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes. Implications for atherosclerosis and transplantation-associated atherosclerosis. Circ Res 2002;90:703–710.
202. Robins SJ. PPAR-α ligands and clinical trials: cardiovascular risk reduction with fibrates. J Cardiovasc Risk 2001;4:203–210.
203. Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002;40:687–693.
204. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372–1378.
205. Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321–329. [Discusses the molecular mechanisms by which angiotensin-II contributes to the proinflammatory pathways involved in the development of atherosclerosis, hypertension, and renal damage.]
206. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:568–574.
207. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669–677.
208. Lindholm LH, Ibsen H, Dahlöf B, et al., for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359: 1004–1010.